Please use this identifier to cite or link to this item:
|Title:||Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases.|
|Authors:||Muralidharan, Vijayaragavan;Kwok, Marco;Lee, Sze Ting;Lau, Lawrence F;Scott, Andrew M;Christophi, Christopher|
|Affiliation:||Department of Surgery, Austin Hospital, University of Melbourne, Victoria, Australia. firstname.lastname@example.org|
|Citation:||Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2012; 53(9): 1345-51|
|Abstract:||Modern multidisciplinary therapy for colorectal liver metastases (CRLM) is associated with significant morbidity and must be adapted to the patient's relative risk. The tools currently available to risk-stratify patients are limited. This study assessed the prognostic utility of metabolic measurements derived from(18)F-FDG PET compared with previously proposed prognostic scoring systems.Preoperative (18)F-FDG PET/CT studies from a series of 30 patients who underwent liver resection for CRLM after neoadjuvant chemotherapy were evaluated. Quantitative (18)F-FDG PET analysis calculated the maximum and mean standardized uptake value, metabolic tumor volume (MTV), and tumor glycolytic volume (TGV) as measures of the metabolic activity of tumors. The predictive value of these parameters was compared with that of 4 prognostic scores developed by Fong, Iwatsuki, Nordlinger, and Rees.High MTV and TGV in patients before metastasectomy were significantly associated with poorer overall survival (MTV: P = 0.001; TGV: P = 0.004) and recurrence-free survival (MTV: P = 0.001, TGV; P = 0.002). Maximum and mean standardized uptake value did not show any significant predictive ability. Of the prognostic scores, prediction of outcome was most accurate using the Basingstoke index (area under the curve, 0.898).Assessment of metabolic tumor burden with volumetric (18)F-FDG PET parameters appears to be a valuable adjunct in determining the biology of CRLM before surgical resection and may enable better risk stratification of patients.|
|Internal ID Number:||22797376|
Aged, 80 and over
Fluorodeoxyglucose F18.diagnostic use
Liver Neoplasms.metabolism.pathology.radionuclide imaging.secondary
Tomography, X-Ray Computed
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.